Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
TMPyP4 tosylateCat. No. 4253 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 5,10,15,20-Tetrakis(1-methylpyridinium-4-yl)porphyrin tetra(p-toluenesulfonate) |
Biological Activity
Cationic porphyrin; inhibits human telomerase. Stacks with G tetrads to stabilize quadruplex DNA. Inhibits cell proliferation and induces cell death in three myeloma cell lines. Activity results in telomere shortening at concentrations between 1 and 5 μM.Certificate of Analysis / Safety Data Sheet
References
Wheelhouse et al (1998) Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA. J.Am.Chem.Soc. 120 3261.
Rha et al (2000) Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. Clin.Cancer Res. 6 987. PMID: 10741725.
Shi et al (2001) Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrins and structure-activity relationship for the inhibition of telomerase. J.Med.Chem. 474 4509.
Shammas et al (2003) Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol.Cancer Ther. 2 825. PMID: 14555701.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: TMPyP4 tosylate, supplier, TMPyP4, telomerase, inhibitors, g, tetrads, quadruplex, DNA, telomeres
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
New Products in this Area
Tankyrase inhibitor; inhibits Wnt signaling
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.